Brand-Name vs Compounded GLP-1

For two years the compounded GLP-1 market ran on a straightforward logic. Brand-name semaglutide cost over $1,000 a month, compounded copies cost $200, and the FDA drug shortage lists made large-scale compounding permissible. If you were paying cash, compounded was often the only realistic option.

Both halves of that logic have now changed. The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025, ending the shortage-based enforcement discretion. It has since proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them.

Meanwhile manufacturer-direct pricing collapsed. Foundayo starts at $149 a month. Wegovy tablets start at $149. Zepbound starts at $299 against a $499 to $1,086 list price per fill. The price gap that justified the trade-off has largely closed.

What compounding actually is

A compounding pharmacy prepares a medication from raw ingredients rather than dispensing a manufactured product. It is a legitimate and long-standing part of medicine, and it exists for genuine reasons: a patient who needs a dose strength that is not commercially made, a liquid formulation for someone who cannot swallow tablets, an allergy to a dye or filler in the approved product.

What compounding is not is a generic. A generic drug goes through an FDA approval process demonstrating bioequivalence to the brand. A compounded drug does not. The FDA does not evaluate compounded products for safety, effectiveness or quality — it is not that they failed a review, it is that no review happens.

That distinction is the whole thing. Compounded semaglutide contains semaglutide, but "contains the active ingredient" and "has been verified to deliver the right amount of it, consistently, with acceptable purity and stability" are different claims.

The differences that matter

Where compounded still has a genuine case

Being fair about this matters. Compounding is not inherently illegitimate, and there are real scenarios where it remains the better answer.

• You need a dose strength that is not commercially manufactured — a genuinely personalised dose rather than a copy of an approved one.
• You are following a microdosing protocol at doses below the lowest approved strength.
• You need a formulation the brands do not sell, such as sublingual drops or a combination with B12 or B6.
• You have a documented sensitivity to an excipient in the approved product.
• You have found a verified all-in price meaningfully below $149 a month and you are making the trade-off knowingly.

Note that a compounded product which is essentially a copy of an approved drug at an approved strength is exactly the category the FDA has moved against.

Where brand-name is now clearly better

• You have insurance that covers weight-management medication. Compounded is never covered, so choosing it means paying cash unnecessarily.
• You are Medicare-eligible. The GLP-1 Bridge program covers Foundayo tablets, Wegovy and the Zepbound KwikPen at $50 a month from July 1, 2026 — no compounded product qualifies.
• You want standard dosing at standard strengths. At $149 a month for Foundayo or Wegovy tablets, there is no longer a price argument.
• You want certainty that the product will still exist in six months. The regulatory basis for compounded GLP-1s has narrowed substantially.
• You want to rely on HSA or FSA reimbursement, which is straightforward for approved medication and uncertain for compounded.
• You want the drug that was actually studied in the trials whose results persuaded you to try a GLP-1 in the first place.

How to reduce risk if you choose compounded

If, having weighed all of that, compounded is still the right answer for your situation, a few things meaningfully reduce your exposure.

Ask which compounding pharmacy prepares your medication, and whether it is a 503A pharmacy or a 503B outsourcing facility. Most telehealth platforms do not volunteer this. A provider that will not tell you is telling you something.

Check the FDA warning letter database for the provider and the pharmacy before you enrol. This is a two-minute search and it surfaced a September 2025 warning letter for one popular low-cost provider in our own review process.

Avoid prepaying twelve months. The cheapest advertised rates almost always require annual prepayment, and some auto-renew. In a category where availability is genuinely uncertain, that is a poor bet.

Be sceptical of prices far below the market. The FDA has specifically warned about fraudulent compounded products with false label information, and unusually cheap is a reasonable trigger for more questions.

Keep a prescriber involved regardless. Whatever the product, GLP-1 therapy needs dose titration, side-effect management and monitoring by someone qualified.

Frequently Asked Questions

Keep Reading

Sources

Claims on this page trace to the following sources, checked on August 30, 2026.

• •FDA — Concerns with unapproved GLP-1 drugs used for weight loss
• •FDA — Clarification of policies for compounders as GLP-1 supply stabilizes
• •FDA — Proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list
• •FDA — Warning letters to telehealth companies over compounded GLP-1 claims
• •GoodRx — Are compounded GLP-1s going away?
• •Medicare.gov — Weight loss drugs coverage